201
|
González-García I, Mangas-Sanjuán V, Merino-Sanjuán M, Bermejo M. In vitro–in vivocorrelations: general concepts, methodologies and regulatory applications. Drug Dev Ind Pharm 2015; 41:1935-47. [DOI: 10.3109/03639045.2015.1054833] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
202
|
Vaithianathan S, Raman S, Jiang W, Ting TY, Kane MA, Polli JE. Biopharmaceutic Risk Assessment of Brand and Generic Lamotrigine Tablets. Mol Pharm 2015; 12:2436-43. [DOI: 10.1021/acs.molpharmaceut.5b00154] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Soundarya Vaithianathan
- Department
of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland 21201, United States
| | - Siddarth Raman
- Department
of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland 21201, United States
| | - Wenlei Jiang
- Food and Drug Administration, Rockville, Maryland 20852, United States
| | - Tricia Y. Ting
- Department
of Neurology, University of Maryland, Baltimore, Maryland 21201, United States
| | - Maureen A. Kane
- Department
of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland 21201, United States
| | - James E. Polli
- Department
of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland 21201, United States
| |
Collapse
|
203
|
Matsui K, Tsume Y, Amidon GE, Amidon GL. In Vitro Dissolution of Fluconazole and Dipyridamole in Gastrointestinal Simulator (GIS), Predicting in Vivo Dissolution and Drug–Drug Interaction Caused by Acid-Reducing Agents. Mol Pharm 2015; 12:2418-28. [DOI: 10.1021/acs.molpharmaceut.5b00135] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Affiliation(s)
- Kazuki Matsui
- College
of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, Michigan 48109-1065, United States
- Pharmacokinetics
and Safety Laboratory, Discovery Research, Pharmaceutical Research
Center, Mochida Pharmaceutical Company Limited, 722 Uenohara, Jimba, Gotemba, Shizuoka 412-8524, Japan
| | - Yasuhiro Tsume
- College
of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, Michigan 48109-1065, United States
| | - Gregory E. Amidon
- College
of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, Michigan 48109-1065, United States
| | - Gordon L. Amidon
- College
of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, Michigan 48109-1065, United States
| |
Collapse
|
204
|
Yu LX, Baker J, Berlam SC, Boam A, Brandreth EJ, Buhse L, Cosgrove T, Doleski D, Ensor L, Famulare J, Ganapathy M, Grampp G, Hussong D, Iser R, Johnston G, Kesisoglou F, Khan M, Kozlowski S, Lacana E, Lee SL, Miller S, Miksinski SP, Moore CMV, Mullin T, Raju GK, Raw A, Rosencrance S, Rosolowsky M, Stinavage P, Thomas H, Wesdyk R, Windisch J, Vaithiyalingam S. Advancing Product Quality: a Summary of the Inaugural FDA/PQRI Conference. AAPS JOURNAL 2015; 17:1011-8. [PMID: 25840884 DOI: 10.1208/s12248-015-9754-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/24/2015] [Accepted: 03/16/2015] [Indexed: 11/30/2022]
Abstract
On September 16 and 17, 2014, the Food and Drug Administration (FDA) and Product Quality Research Institute (PQRI) inaugurated their Conference on Evolving Product Quality. The Conference is conceived as an annual forum in which scientists from regulatory agencies, industry, and academia may exchange viewpoints and work together to advance pharmaceutical quality. This Conference Summary Report highlights key topics of this conference, including (1) risk-based approaches to pharmaceutical development, manufacturing, regulatory assessment, and post-approval changes; (2) FDA-proposed quality metrics for products, facilities, and quality management systems; (3) performance-based quality assessment and clinically relevant specifications; (4) recent developments and implementation of continuous manufacturing processes, question-based review, and European Medicines Agency (EMA)-FDA pilot for Quality-by-Design (QbD) applications; and (5) breakthrough therapies, biosimilars, and international harmonization, focusing on ICH M7 and Q3D guidelines. The second FDA/PQRI conference on advancing product quality is planned for October 5-7, 2015.
Collapse
Affiliation(s)
- Lawrence X Yu
- Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, Maryland, 20993, USA,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
205
|
Ottaviani G, Wendelspiess S, Alvarez-Sánchez R. Importance of Critical Micellar Concentration for the Prediction of Solubility Enhancement in Biorelevant Media. Mol Pharm 2015; 12:1171-9. [DOI: 10.1021/mp5006992] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- G. Ottaviani
- Roche
Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Shanghai, F. Hoffmann-La Roche Ltd, 720 Cai Lun Road, Building
5 Pudong, Shanghai 201203, China
| | - S. Wendelspiess
- Roche
Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - R. Alvarez-Sánchez
- Roche
Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| |
Collapse
|
206
|
Wu C, Kou L, Ma P, Gao L, Li B, Li R, Luo C, Shentu J, He Z, Sun J. Interspecies prediction of oral pharmacokinetics of different lacidipine formulations from dogs to human: physiologically based pharmacokinetic modelling combined with biorelevant dissolution. RSC Adv 2015. [DOI: 10.1039/c4ra16017g] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
PBPK modelling combined with biorelevant dissolution to quantitatively predict dog PK of different lacidipine formulations, and to extrapolate to human.
Collapse
Affiliation(s)
- Chunnuan Wu
- Department of Pharmaceutics
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
| | - Longfa Kou
- Department of Pharmaceutics
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
| | - Panqin Ma
- Kangya of Ningxia Pharmaceuticals Co. Ltd
- China
| | - Lifang Gao
- Department of Pharmaceutics
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
| | - Bo Li
- Department of Pharmaceutics
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
| | - Ran Li
- Department of Pharmaceutics
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
| | - Cong Luo
- Department of Pharmaceutics
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
| | - Jianzhong Shentu
- The First Affiliated Hospital of College of Medicine
- Zhejiang University
- China
| | - Zhonggui He
- Department of Pharmaceutics
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
| | - Jin Sun
- Department of Pharmaceutics
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
| |
Collapse
|
207
|
Mudie DM, Murray K, Hoad CL, Pritchard SE, Garnett MC, Amidon GL, Gowland PA, Spiller RC, Amidon GE, Marciani L. Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state. Mol Pharm 2014; 11:3039-47. [PMID: 25115349 DOI: 10.1021/mp500210c] [Citation(s) in RCA: 347] [Impact Index Per Article: 34.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The rate and extent of drug dissolution and absorption from solid oral dosage forms is highly dependent upon the volumes and distribution of gastric and small intestinal water. However, little is known about the time courses and distribution of water volumes in vivo in an undisturbed gut. Previous imaging studies offered a snapshot of water distribution in fasted humans and showed that water in the small intestine is distributed in small pockets. This study aimed to quantify the volume and number of water pockets in the upper gut of fasted healthy humans following ingestion of a glass of water (240 mL, as recommended for bioavailability/bioequivalence (BA/BE) studies), using recently validated noninvasive magnetic resonance imaging (MRI) methods. Twelve healthy volunteers underwent upper and lower abdominal MRI scans before drinking 240 mL (8 fluid ounces) of water. After ingesting the water, they were scanned at intervals for 2 h. The drink volume, inclusion criteria, and fasting conditions matched the international standards for BA/BE testing in healthy volunteers. The images were processed for gastric and intestinal total water volumes and for the number and volume of separate intestinal water pockets larger than 0.5 mL. The fasted stomach contained 35 ± 7 mL (mean ± SEM) of resting water. Upon drinking, the gastric fluid rose to 242 ± 9 mL. The gastric water volume declined rapidly after that with a half emptying time (T50%) of 13 ± 1 min. The mean gastric volume returned back to baseline 45 min after the drink. The fasted small bowel contained a total volume of 43 ± 14 mL of resting water. Twelve minutes after ingestion of water, small bowel water content rose to a maximum value of 94 ± 24 mL contained within 15 ± 2 pockets of 6 ± 2 mL each. At 45 min, when the glass of water had emptied completely from the stomach, total intestinal water volume was 77 ± 15 mL distributed into 16 ± 3 pockets of 5 ± 1 mL each. MRI provided unprecedented insights into the time course, number, volume, and location of water pockets in the stomach and small intestine under conditions that represent standard BA/BE studies using validated techniques. These data add to our current understanding of gastrointestinal physiology and will help improve physiological relevance of in vitro testing methods and in silico transport analyses for prediction of bioperformance of oral solid dosage forms, particularly for low solubility Biopharmaceutics Classification System (BCS) Class 2 and Class 4 compounds.
Collapse
Affiliation(s)
- Deanna M Mudie
- College of Pharmacy, University of Michigan , Ann Arbor, Michigan 48109-1065, United States
| | | | | | | | | | | | | | | | | | | |
Collapse
|
208
|
Shah VP, Amidon GL. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm Res 12, 413-420, 1995--backstory of BCS. AAPS JOURNAL 2014; 16:894-8. [PMID: 24961917 DOI: 10.1208/s12248-014-9620-9] [Citation(s) in RCA: 72] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/25/2014] [Accepted: 05/12/2014] [Indexed: 11/30/2022]
Abstract
The Biopharmaceutics Classification System (BCS) has become widely accepted today in the academic, industrial, and regulatory world. While the initial application of the BCS was to regulatory science bioequivalence (BE) issues and related implications, it has come to be utilized widely by the pharmaceutical industry in drug discovery and development as well. This brief manuscript will relate the story of the BCS development. While much of the ground work for the BCS goes back to the pharmacokinetic and drug absorption research by Gordon Amidon (GLA) in the 1970s and 1980s, the realization of the need for a classification or categorization of drug and drug products for setting dissolution standards became apparent to GLA during his 1990-1991 sabbatical year at the FDA. Initiated at the invitation of the then CEDR director, Dr. Carl Peck, to become a visiting scientist at the FDA, the goal was to promote regulatory research at the FDA, in my case, in biopharmaceutics, and to develop a science-based system to simplify regulatory requirements.
Collapse
Affiliation(s)
- Vinod P Shah
- Pharmaceutical Consultant, North Potomac, Maryland, 20878, USA
| | | |
Collapse
|